What is Agenus's gross profit margin?

What is Agenus's latest dividend and current dividend yield?

What is the revenue and EPS growth rate for Agenus year over year?

What is the market's earnings forecast for Agenus next quarter?

What were the key takeaways from Agenus's earnings call?

What guidance did Agenus's management provide for the next earnings period?

Did Agenus beat or miss consensus estimates last quarter?

What factors drove the changes in Agenus's revenue and profit?

- **Breakthrough Potential in MSS CRC**: BOT/BAL achieves 42% 2-year survival in late-line MSS CRC, far exceeding current standards (10-14 months). 
- **Phase III Trial Launch**: BATTMAN trial to enroll 834 patients globally, targeting late-line MSS CRC with BOT/BAL vs best supportive care.
- **Neoadjuvant Success**: 40%+ complete responses in early-stage MSS CRC, breast, and sarcoma patients, avoiding chemotherapy.
- **Regulatory Advocacy**: Pushing FDA for accelerated approval pathways to save lives while trials are ongoing.
- **Manufacturing Expansion**: Zydus collaboration to optimize production, reducing costs and enhancing scalability.

**【CEO Summary Section】**
- Agenus is focused on advancing its BOT/BAL immunotherapy combination for metastatic colorectal cancer (mCRC), particularly targeting the 85% of patients with microsatellite stable (MSS) tumors who lack effective treatment options.
- Phase I/II data shows a 42% 2-year survival rate in late-line MSS CRC patients, significantly outperforming current standards (10-14 months), with manageable side effects.
- The company is collaborating with the Canadian Cancer Trials Group (CCTG) to initiate a Phase III trial (BATTMAN) in late-line MSS CRC, aiming to enroll 834 patients across Canada, Australia, and France.
- Regulatory challenges include FDA delays in approving an accelerated pathway, despite strong efficacy signals. The company is advocating for reforms to align regulatory timelines with scientific progress.

**【Q&A Highlights】**
- **Phase III Trial Design**: The BATTMAN trial will randomize patients 1:1 between BOT/BAL and best supportive care, with a focus on MSS CRC patients who have exhausted standard therapies. Enrollment is expected to begin in Q4 2025, with 60 patients/month projected.
- **Neoadjuvant Strategy**: Early-stage trials (e.g., NEST, UNICORN) show 40%+ complete responses in MSS CRC, breast, and sarcoma patients, highlighting potential for organ preservation and chemotherapy-free treatment.
- **Regulatory Advocacy**: Agenus is engaging with FDA Commissioner Dr. Makary to push for reforms enabling earlier access to innovative therapies like BOT/BAL.
- **Zydus Collaboration**: The transfer of Agenus' Emeryville manufacturing facility to Zydus is nearing completion, with Hart-Scott-Rodino clearance achieved and final Treasury approval expected in 2-3 weeks. This partnership aims to reduce costs and expand manufacturing capacity.

Agenus (AGEN)-27 Aug 25-2025 Q2 Earnings call transcript

- **Breakthrough Data**: BOT/BAL shows 4x+ response rates vs. standard care in metastatic CRC, with 2-year follow-up survival data
- **FDA Momentum**: Type B meeting requested; CHMP agrees on trial design for European conditional approval
- **Cash Flow Fix**: Annualized burn to drop below $50M; multiple capital transactions expected within weeks
- **Strategic Shift**: Neoadjuvant CRC could eliminate surgery/radiation for young patients, addressing unmet need in under-50 population

**【CEO Opening Remarks】**
- **BOT/BAL Data Highlights**: Mature data showing durable responses in MSS colorectal cancer, hepatocellular carcinoma, and sarcomas. NEOASIS trial demonstrated 100% surgical proceed rate with no dose-limiting toxicities.
- **New Leadership**: Dr. Richard Goldberg (GI oncology expert) joins as Chief Development Officer to steer regulatory filings for metastatic CRC.
- **Operational Efficiency**: Annualized cash burn expected to drop below $50M in H2 2025, freeing resources for BOT/BAL expansion.
- **Capital Strategy**: 4 formal proposals received, including Emeryville facility sale, equity investment at premium, and global licensing deals. At least one transaction expected within weeks.
- **FDA Engagement**: Requested Type B meeting to discuss accelerated approval for BOT/BAL, supported by 1,200+ patient data with 2-year follow-up.

**【CFO Financial Review】**
- **Q1 2025 Financials**: 
  - Cash balance: $18.5M (down from $40.4M at year-end 2024)
  - Net loss: $26.4M (-$1.03/share) vs. $63.5M (-$3.04/share) in Q1 2024
  - Revenue: $24.1M (down 14% YoY) driven by non-cash royalties
- **Cash Flow**: Operating expenses down 33% YoY to $25.6M

**【Q&A Key Takeaways】**
1. **Regulatory Path**: 
   - FDA Type B meeting expected within weeks
   - Phase 2 data maturation shows 4x+ improvement in response rates vs. standard care
   - CHMP in Europe agrees on randomized trial design for conditional approval
2. **Clinical Strategy**: 
   - Focus on metastatic CRC (3rd/4th line) and neoadjuvant CRC
   - BOT/BAL safety profile enables earlier intervention (e.g., 4-8 week tumor resolution in neoadjuvant setting)
3. **Capital Execution**: 
   - Global licensing deals would fully outsource trial costs
   - Emeryville facility sale could close within 6-12 months
4. **FDA Dynamics**: 
   - New administration emphasizes "meaningful treatments"
   - Previous FDA decision based on flawed literature excluding CTLA-4 data
   - Agency now open to accelerated approval if data demonstrates durable responses

Agenus Inc. (AGEN) Q1 2025 Earnings Call Transcript

- **Burn Rate Achievement**: Annualized operational burn reduced to $50M, 31% lower than prior year. 
- **BOT/BAL Breakthrough**: Durable responses in 90% of colorectal cancers, with potential for surgery-free treatment. 
- **Financial Focus**: $40.4M cash on hand; prioritizing BOT/BAL development amid $232M net loss. 
- **Partnership Push**: Seeking funding for intermediate-stage colon/rectal cancer trials to accelerate approvals.

**【CEO Opening Remarks】**
- **Operational Efficiency**: Reduced annualized burn rate to $50 million by mid-2024, down from $158 million in 2023. 
- **BOT/BAL Clinical Momentum**: 
  - MSS colorectal cancer: Durable responses & prolonged survival in refractory cases. 
  - MSI-high CRC: Near-complete pathological responses in neoadjuvant settings. 
  - Potential for surgery-free options in rectal cancer. 
- **Strategic Partnerships**: Engaging in late-stage discussions for BOT/BAL development funding, focusing on intermediate-stage colon & rectal cancer. 
- **Asset Optimization**: Monetizing biologics manufacturing facilities & land assets to bolster balance sheet. 

**【CFO Financial Review】**
- **Cash Position**: $40.4 million as of Q4 2024 (vs. $76.1 million in 2023). 
- **Revenue**: $103.5 million for FY2024 (90% non-cash royalties). 
- **Net Loss**: $232.3 million (FY2024) / $46.8 million (Q4 2024). 
- **Burn Rate**: FY2024 cash used in operations: $158 million (31% YoY reduction). 

**【CEO Closing Remarks】**
- Acknowledged financial constraints but emphasized strategic focus on high-potential assets like BOT/BAL. 
- reiterated commitment to reducing costs while maximizing clinical & commercial value of lead programs.

Agenus (AGEN)-11 Mar 25-2024 Q4 Earnings call transcript

Agenus (AGEN)-12 Nov 24-2024 Q3 Earnings call transcript

Agenus (AGEN)-8 Aug 24-2024 Q2 Earnings call transcript

Agenus (AGEN)-7 May 24-2024 Q1 Earnings call transcript

Agenus (AGEN)-14 Mar 24-2023 Q4 Earnings call transcript

Agenus (AGEN)-7 Nov 23-2023 Q3 Earnings call transcript

Agenus (AGEN)-9 May 23-2023 Q1 Earnings call transcript

Agenus (AGEN)-14 Mar 23-2022 Q4 Earnings call transcript

Agenus (AGEN)-8 Nov 22-2022 Q3 Earnings call transcript

Agenus (AGEN)-9 Aug 22-2022 Q2 Earnings call transcript

Agenus (AGEN)-10 May 22-2022 Q1 Earnings call transcript

Agenus (AGEN)-1 Mar 22-2021 Q4 Earnings call transcript

Agenus (AGEN)-9 Nov 21-2021 Q3 Earnings call transcript

Agenus (AGEN)-9 Aug 21-2021 Q2 Earnings call transcript

Agenus (AGEN)-6 May 21-2021 Q1 Earnings call transcript

Agenus (AGEN)-15 Mar 21-2020 Q4 Earnings call transcript

Agenus (AGEN)-29 Oct 20-2020 Q3 Earnings call transcript

Agenus (AGEN)-6 Aug 20-2020 Q2 Earnings call transcript

Agenus (AGEN)-7 May 20-2020 Q1 Earnings call transcript

Agenus (AGEN)-12 Mar 20-2019 Q4 Earnings call transcript

Agenus (AGEN)-4 Nov 19-2019 Q3 Earnings call transcript

Agenus (AGEN)-8 Aug 19-2019 Q2 Earnings call transcript

Agenus (AGEN)-9 May 19-2019 Q1 Earnings call transcript

Agenus (AGEN)-14 Mar 19-2018 Q4 Earnings call transcript

Agenus (AGEN)-6 Nov 18-2018 Q3 Earnings call transcript

Agenus (AGEN)-9 Aug 18-2018 Q2 Earnings call transcript

Agenus (AGEN)-7 May 18-2018 Q1 Earnings call transcript

Agenus (AGEN)-15 Mar 18-2017 Q4 Earnings call transcript

Agenus (AGEN)-7 Nov 17-2017 Q3 Earnings call transcript

Actual											-6.0841	-5.4953	-5.4953	-3.9252	-5.299	-7.2617	14.1308	-5.1658	-3.729	-3.3364	-3.729	-4.7103	-4.4	-4	-3.2	-2.6	-3.04	-2.52	-3.08	-2.04	-1.03	-1	1.94	-0.6
Forecast											-6.542	-5.3645	-5.1028	-4.3177	-6.0187	-4.7757	8.9626	-3.0911	-5.8388	-4.514	-3.6799	-4.3505	-4.142	-3.9	-3.9013	-1.0675	-3.2068	-1.0666	-2.3137	-2.542	-1.6542	2.42	2.1967	-1.0433
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+7.00%	-2.44%	-7.69%	+9.09%	+11.96%	-52.06%	+57.66%	-67.12%	+36.13%	+26.09%	-1.33%	-8.27%	-6.23%	-2.56%	+17.98%	-143.56%	+5.20%	-136.26%	-33.12%	+19.75%	+37.73%	-141.32%	-11.69%	+42.49%

Actual	--	--	--	--	--	--	--	--	--	--	15.13M	26.95M	14.83M	31.27M	11.72M	10.73M	252.95M	20.26M	25.94M	20.93M	22.77M	28.39M	22.90M	25.30M	24.31M	83.80M	28.00M	23.51M	25.11M	26.84M	24.07M	25.70M	30.20M	28.00M
Forecast	--	--	--	--	--	--	--	--	--	--	12.35M	9.33M	14.00M	16.23M	14.53M	20.41M	183.10M	37.74M	11.80M	18.70M	20.69M	17.83M	22.98M	24.13M	24.33M	47.05M	47.17M	63.48M	33.48M	30.27M	21.98M	49.71M	80.39M	28.10M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+22.45%	+188.84%	+5.95%	+92.60%	-19.36%	-47.43%	+38.15%	-46.31%	+119.82%	+11.93%	+10.05%	+59.24%	-0.32%	+4.82%	-0.07%	+78.09%	-40.63%	-62.97%	-24.99%	-11.35%	+9.48%	-48.30%	-62.43%	-0.34%

AGEN

AGEN fundamentals

AGEN Q4 2025 Earnings

Earnings Call

You can ask Aime

AGEN

AGEN fundamentals

AGEN Q4 2025 Earnings

Earnings Call

AGEN Earnings Call Summary for Q4/2025 Apr 2, 2026

AGEN Earnings Call Summary for Q3/2025 Apr 2, 2026

AGEN Earnings Call Summary for Q2/20254:30 PM on Aug 27, 2025

AGEN Earnings Call Summary for Q1/20258:30 AM on May 12, 2025

AGEN Earnings Call Summary for Q4/20248:30 AM on Mar 11, 2025

You can ask Aime